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Functioning can be defined as the ability to perform daily activities, and to main-
tain interpersonal relationships and work capacity/productivity. Major Depressive 
Disorder (MDD) is associated with substantial impairment in functioning. The 
study examined associations between various measures of functioning (patient 
assessment) and MDD symptoms (clinician assessment). A major challenge was 
to ensure MDD patient compliance with regular self-assessments and retention in 
a long-term study.Objectives: The purpose of the Direct to Patient Contact (DPC) 
approach was to maximize patient compliance to Patient Reported Outcomes 
(PRO) data collection and retention in a study conducted in real life settings over 
a two-year follow-up period. MethOds: This was an international, multicentric, 
observational, prospective longitudinal cohort study involving 1,500 MDD patients 
followed-up for two years in five European countries. Patients were recruited by 
General Practitioners or psychiatrists and data collected using a hybrid method: 
clinical data by physicians and PRO data self-assessment by patients. DPC actions 
included PRO questionnaire shipments to patients at five time points, followed 
by phone reminder contacts for non-returned questionnaires. Results: 1,450 
patients were included in the study, 97.8% of whom agreed to be contacted directly 
by DPC staff. Overall, 71.7% of patients were reached by phone and 75.6% of PRO 
questionnaires were returned; the questionnaire completion rate reached 95.3%. 
79.6% of patients remained until study end, 0.1% died, 3.5% voluntarily with-
drew from the study and 16.7% were withdrawn for other reasons. There were 
no patients lost to follow up. cOnclusiOns: This study demonstrates that the 
use of DPC in a MDD population, likely to be study non-compliant/unresponsive, 
produced excellent long-term response rates. It minimized voluntary patient 
drop-outs and lost to follow up rates, and ensured an enhanced data collection of 
self-assessed PROs, thus improved reliability of study outcomes.
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Objectives: Excess chin and neck fat adversely affects facial appearance, producing 
measureable negative impacts on psychological health and psychosocial function. 
The Patient-Reported Submental Fat Impact Scale (PR-SMFIS) is a patient-reported 
outcome (PRO) measure developed and validated to assess submental fat (SMF)-
associated psychological impact and its improvement associated with the reduction 
of SMF with deoxycholic acid (DCA) injection (ATX-101) as an injectable treatment 
for SMF. MethOds: Scale development and validation followed global regulatory 
guidelines and industry best practices. A conceptual model and draft response 
items were developed based on literature review, key opinion leader interviews, and 
patient concept elicitation interviews. The resulting 6-item scale assesses negative 
psychological impact of SMF on emotional perceptions (happiness, self-conscious-
ness, bothersomeness, and embarrassment) and visual perceptions (looking older 
and overweight). Items are rated on an 11-point scale (0 = no impact, 10 = extreme 
negative impact); the total scale score is the average response. Six clinical trials of 
ATX-101 for SMF treatment provide assessments of reliability, construct validity, 
sensitivity to change, and score interpretation. PR-SMFIS validity was assessed using 
two generic measures of psychological impact, the Derriford Appearance Scale-24 
(DAS-24) and Body Image Quality of Life Inventory (BIQLI). Results: The PR-SMFIS 
demonstrated high test-retest reliability (Intra-class correlation = 0.75), internal 
consistency (Cronbach’s alpha › 0.92), external validity against the DAS-24 (r = 0.57) 
and BIQLI (r = -0.3), and patient SMF ratings (r = 0.49 to 0.75). SMF treatment pro-
duced large effect sizes (Cohen ES = -2) consistent with effect sizes for clinician and 
patient ratings, and objective measures of SMF reduction. cOnclusiOns: These 
results confirm that PR-SMFIS is a content-valid PRO instrument with robust reli-
ability and validity for SMF psychological impact assessment.
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Objectives: To determine which patient-reported outcome (PRO) and car-
egiver quality of life tools were used in studies on dementia published in 
2014. MethOds: An evidence surveillance process was established based on a 
systematic search of PubMed, incorporating all studies published from 2010 and 
updated weekly, with a final search on 18 May 2015. Abstracts identified by the 
search that reported humanistic burden outcomes in dementia were identified. 
Articles were included if they reported results or a study protocol from a primary 
research study or were a systematic review. PRO tools were identified, where 
possible, from the abstract alone. Results: Of 1,980 articles published in 2014 
identified by the search for PROs and quality of life, 32 were relevant to patients 
and/or caregivers of adults with dementia, cognitive impairment or memory loss. 
The PRO used was not specified in 17 abstracts, but 19 different PRO or caregiver-
reported instruments were cited in the remaining 15 abstracts. Dementia-specific 
instruments included the Quality of life-Alzheimer’s disease (QoL-AD), used in 6 
studies, and the Alzheimer’s Disease Assessment Scale - Cognition (ADAS-Cog), the 
Five-Cog test, the Metamemory in Adulthood Questionnaire and the Mild Cognitive 
Impairment Questionnaire (MCQ), used in 1 study each. Despite the substantial 
burden on caregivers, only 8 studies reported outcomes related to the humanistic 
burden in this population. Instruments used in caregivers included generic utility 
measures, the QOL-AD, and the Zarit Burden Interview, but were not specified in 
5 abstracts. Utilities were measured in only 3 studies, with Short Form (12 or 36) 
used in all 3 studies and EQ-5D in one. Depression was assessed in 2 studies of 
lowed by the UK (13), the Netherlands (7) and Germany (4). Despite the high societal 
costs associated with mental illness, this was generally under-reported, with just 
26 of the 76 articles reporting indirect social, productivity, informal care or criminal 
justice costs. In comparison, direct costs were evaluated in 48 articles and healthcare 
resource use in 38 articles. Indirect costs were reported in 6 of the 7 studies from 
the Netherlands, compared with 4 of the 13 UK studies and 6 of the 31 USA studies. 
Caregiver burden was assessed in just 3 studies, one each on dementia, autism and 
depression. cOnclusiOns: Recent research on economic burden in mental health 
disorders has focused disproportionately on the management of substance abuse 
and on direct costs or healthcare resource use. Up-to-date data on indirect costs 
from other chronic mental disorders remains sparse.
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Objectives: Some studies on the effects of adherence and persistence to antipsy-
chotics on healthcare use suggested negative associations between adherence and 
resource utilization, whereas several other studies suggested positive associations 
or no associations. This study aims to estimate the impacts of adherence and per-
sistence to atypical antipsychotics on costs and hospitalization by reducing possible 
endogeneity. MethOds: To examine the effects of adherence (proportion of days 
covered) and persistence (time-to-discontinuation) to atypical antipsychotics in 
the first year following the initiation of atypical antipsychotic therapy on costs and 
hospitalization in the second year, we carried out retrospective analysis of 2007-2013 
Humana claims data. Individuals in the databases with a diagnosis of schizophrenia 
or bipolar disorder at any time and had a prescription for non-injectable atypical 
antipsychotics were identified and selected. Instrumental variable (IV) regressions 
using reimbursement rate and mail order as IVs were conducted to correct poten-
tial endogeneity. Results: Being adherent was associated with decreased total 
costs by US$19,497 (p< 0.05), increased medication costs by US$8,194 (p< 0.001), 
decreased medical services costs by US$27,664 (p< 0.001), and reduced hospitaliza-
tion risk by 27% (p< 0.001). Being persistent was associated with decreased indi-
vidual total costs by US$23,927 (p< 0.05), increased medication costs by US$10,278 
(p< 0.001), and decreased medical services costs by US$34,178 (p< 0.001). We could 
not identify significant association between persistence and the risk of hospitaliza-
tion. cOnclusiOns: Good adherence and persistence to atypical antipsychotics 
lead to lower total costs than poor adherence and persistence. Efforts should be 
made to improve adherence and persistence.
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bAckgROund: Adherence to antidepressant treatment is demanded for both 
clinical and economic effectiveness in treated depression. The Lam Employment 
Absence and Productivity Scale (LEAPS) was acquired, re-validated and tested 
in blind randomization with Thai Depression Inventory (TDI). Objectives: 
To assess effects of antidepressant-based treatment among ambulatory Thai 
depressed patients after 3 months completed adherence to treatment with TDI 
and LEAPS. MethOds: Thai depressed patients in public hospital under antide-
pressant-based treatment were follow-up, 50 were completed adherence for 3 
months. The LEAPS and TDI were assessed independently by both psychiatrists 
and hospital pharmacist. Apparent economic impact of treatment was computed 
based on work-absence employed the minimum daily wage-average of workers 
of the region. Results: 107 depressed patients of 26 Men/81 Women, mean(SD) 
age of 41.9(12.0) years, 34(31.8%) had physical illnesses. 25 patients (23.4%) were 
treated by antidepressant only, 82(76.6%) were treated by anti-depressant plus 
other psychotropics. The Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclics 
Antidepressant (TCAs) and others were prescribed at 55(51.4%), 41 (38.3%) 11 
(10.3%). After 3 months follow-up treatment, significant reduction of both TDI 
and LEAPS with mean(SD) score observed from 50 patients with completed adher-
ence to treatment where depressed symptoms score (assessed with TDI) reduced 
from 34.06(13.5) to 15.9(12.9) (p< 0.05) and LEAPS from 18.16(7.3) to 6.9(6.4) (p< 0.05) 
respectively. Both TDI and LEAPS were well correlated (r= 0.84, p< 0.05). During 3 
months treatment period, work absence was reduced from 86% to 36%. Overall eco-
nomic effectiveness of the adherence to treatment among 50 patients treated with 
anti-depressant-based, unless otherwise economic gains in terms of increased 
productivity could be anticipated from 1.4 to 1.7 Mio THB for the complete adher-
ence to treatment group. cOnclusiOns: Completed adherence antidepressant-
based treatment is effective to reduce clinical symptoms of depression with 
reduction of work absence. The LEAPS and TDI are well correlated suggesting 
further evaluation for its benefits in larger depressed working population.
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influence reimbursement at national/regional level were interviewed. Results: 
Interviewed EU5 payers emphasize that there are high administrative costs involved 
with providing opioid substitution products to addicted patients, especially for metha-
done, which generally requires daily clinic visits to allow patients to receive their 
medication under direct supervision. A substitution therapy requiring less-frequent 
clinic visits would decrease administrative costs and could be preferred as long as 
efficacy parameters relative to standard-of-care are maintained. Similarly, surveyed 
EU5 physicians indicate that potential for abuse or diversion and patient compliance 
are major considerations for prescribing a new therapy (15% [Spain] to 24% [France] 
and 28% [UK] and 52% [Spain] of respondents cite these factors, respectively, as a 
top three consideration). The former could be decreased and the latter increased if 
therapies were dosed less frequently. A long-acting buprenorphine injection, such 
as Camurus/Braeburn Pharmaceuticals’ CAM-2038, could, therefore, appeal to both 
payers and prescribers. Indeed, 86-96% of surveyed physicians are willing to prescribe 
CAM-2038 if it establishes a similar efficacy, safety, and tolerability profile to exist-
ing buprenorphine products in clinical trials. cOnclusiOns: The opioid addiction 
market is dominated by generic products. However, while payers and prescribers are 
constrained by tight healthcare budgets, our primary research indicates that new 
brands such as long-acting depot CAM-2038 could gain traction via powerful market-
ing that focuses on their ability to reduce potential for abuse/diversion and increase 
compliance, provided existing efficacy and safety standards are maintained.
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Objectives: Nalmefene (Lundbeck’s Selincro) is the only marketed drug that 
aims to reduce alcohol consumption rather than maintain abstinence in alcohol-
dependent patients. By examining reimbursement and uptake of nalmefene in the 
EU5, we explore market access challenges for the novel treatment pathway this 
drug represents. MethOds: In February 2015, 253 psychiatrists in France, Germany, 
Italy, Spain, and the UK were surveyed regarding their prescribing of nalmefene. In 
addition, 15 EU5 payers involved in determining and regulating access to alcohol 
addiction pharmaceuticals were interviewed. Results: On average, 10% (UK) to 
30% (France) of surveyed physicians’ drug-treated alcohol-addicted patients receive 
nalmefene. The most commonly cited reasons for not prescribing nalmefene are 
unfamiliarity with the drug (especially in the UK), a belief that the treatment goal 
should be abstinence, and preference for another pharmacotherapy. Furthermore, 
20% of all surveyed EU5 psychiatrists cite maintaining abstinence/reducing relapse 
as the greatest unmet need in the pharmacological treatment of alcohol addiction, 
while 18% (UK) to 38% (France) identify efficacy for maintaining complete abstinence 
from alcohol after withdrawal and detoxification as their key driver for prescribing 
a new therapy. Interviewed payers similarly consider nalmefene’s goal of reducing 
alcohol consumption rather than maintaining abstinence to be a reimbursement 
challenge, and one that, alongside perceived modest efficacy, has contributed to 
suboptimal HTA ratings in France and Germany, and to total lack of reimbursement 
in Italy. cOnclusiOns: Perception of abstinence as the main aim of treatment 
for alcohol addiction is a considerable market access hurdle for nalmefene and 
emerging alcohol consumption-reducing agents. Robust superiority over compara-
tors, persuasive marketing that illustrates the benefits of alcohol reduction versus 
abstinence, and effective targeting of national, regional and local stakeholders are 
essential to encourage payers to think beyond the price tag, and to maximize famili-
arity with and use of this novel treatment pathway among prescribers.
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Objectives: To assess the differences in the utilization of drugs indicated for AD 
treatment across different geographic areas in Turkey and to identify the factors 
that may influence possible disparity in the usage. MethOds: Summary data for 
all 81 cities in Turkey have been collected. The data include IMS sales (standard 
unit sales data of all products indicated for AD -memantin, rivastigmin, donepezil, 
galantamin), demographic (age distribution, education level, population density 
etc.), health policy (number of family physicians and specialists, hospital beds, nurs-
ing houses, average hospital admission rate) and affordability data (social security 
coverage rate). We calculated “utilization score” for all cities, dividing the number 
of standard units sold by the number of subjects who are assumed to have AD. A 
composite “indicator score” was calculated for all cities, summing the weighted val-
ues of all indicators. The relationship of the indicators and the composite indicator 
scores with “utilization score” were analyzed by means of Pearson and Spearman 
correlation analysis as needed. Then, a multivariate regression model was built to 
determine the degree of impact of each indicator. Results: There were significant 
differences in the relative utilization of AD treatments among cities and regions. 
Generally industrialized and larger cities had higher utilization than smaller and/
or less-developed cities by means of infrastructure. It is seen from the multivariate 
regression model that, utilization Index increases when SGK coverage rate and 
population density increase and when household size decrease. cOnclusiOns: 
Geographical disparities in the usage are initially assumed to be related to scarci-
ties in healthcare infrastructure and regional socio-economic factors. However, it is 
seen that healthcare infrastructure is less influential on utilization disparity, which 
has found to be highly driven by socio-economics factors including affordability, 
population density (disperse residence) and household size (indirect indicator for 
socio-economy and family member to provide caregiver service in Turkish culture)
patients and one of caregivers. cOnclusiOns: Most study abstracts reporting 
on the humanistic burden in dementia in 2014 did not specify use of a dementia-
specific instrument. Only 25% of studies assessed burden on caregivers, and utility 
values were rarely reported.
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Objectives: To evaluate the association between caregiver’s reported attention-
deficit/hyperactivity disorder (ADHD) medication satisfaction (MS) and child and 
caregiver socio-demographics; ADHD severity; comorbidities; medication attributes; 
treatment classes. MethOds: CAPPA is a cross-sectional online survey of caregivers 
of children (6–17 years) with ADHD receiving pharmacological treatment for ADHD at 
survey completion (2012–2013) in 10 European countries. ADHD Rating Scale Version 
IV (ADHD-RS-IV) total score during treatment interruption (off medication) was used 
as a proxy for baseline severity. Caregivers were asked to rate satisfaction with medi-
cation attributes (Convenience: administration frequency, tablet size; Effectiveness: 
duration of action, time to onset, symptom control; Safety: side effects, abuse/mis-
use potential, dependence/addiction potential) on a 7-point scale ranging from ‘very 
satisfied’ to ‘very dissatisfied’. Children’s comorbidities at baseline/treatment classes 
were also reported by caregivers. Significant factors (p< 0.01) using bivariate and cor-
relation analyses are reported. Results: Among 3688 respondents, 2853 (77%) whose 
child was using ADHD medication at survey completion were evaluated. Children’s 
mean (SD) age was 11.4 (3.1) years, 81% were male; 67% of caregivers were female. 
MS was rated as: very satisfied (20%), satisfied (39%), moderately satisfied (29%), and 
combined neither satisfied nor dissatisfied, moderately dissatisfied, dissatisfied or 
very dissatisfied (12%). Better MS was reported with lower ADHD severity and fewer 
comorbidities. Comorbidities significantly associated with lower MS were anxiety, 
conduct disorder, aggression and oppositional defiant disorder. Medication attributes 
with strongest correlation to MS were symptom control (r= 0.6), duration of action 
(0.5) and time to onset (0.4). Significantly higher MS was associated with caregivers 
who were married, female, employed or a parent with ADHD. MS varied by coun-
try. cOnclusiOns: Lower ADHD severity and fewer comorbidities were associated 
with higher MS. Effectiveness attributes were of highest priority to caregivers and 
MS differed by caregiver characteristics. These factors should be considered when 
making a treatment plan.
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Objectives: Mental Health Disorders impair occupational performance and 
lead to handicap and economic deprivation. The current contribution quantifies 
the degree of these problems among two representative samples of the German 
and the UK population. MethOds: Two representative samples (n= 3,571) of the 
adult population (20-65 years) in Germany and UK were surveyed in 2012 with 
a questionnaire containing information about occupational status, job related 
handicaps, economic and demographic information. From a survey five years 
earlier (2007) information for the same persons about possible mental health 
disorders and their treatment were available. Longitudinal regression analysis 
estimates the impact of mental status on occupational disability and financial 
deprivation Results: In the initial survey 18.5% of the sample suffered from 
depression and 7.0% from anxiety/ phobia. 53.8% of the depressive individuals 
and 56.8% of the individuals suffering from anxiety or phobia were treated by 
General Practitioners or Specialists. Five years later unemployment due to men-
tal health reasons was reported by 57.2% of the persons with treated mental 
health disorders but only by 19.9% of the group with no mental health disorders. 
Individuals with mental disorders needed – among other handicaps - more often 
breaks at work than persons with no disorders (33.3% vs. 8.5%) or could no longer 
perform all elements of their jobs (28.9% vs. 6.9%). Occupational handicap resulted 
in economic deprivation: 28.0% of the treated mental health group reported a 
monthly net income of less than 800GP compared to 13.2% of the group with no 
mental health disorders. cOnclusiOns: Mental Health Disorders have consider-
able impacts on occupational performance, participation in work life and on the 
financial economic situation. Individuals who are under treatment suffer more 
often from these handicaps than untreated - presumably because of their more 
severe disease status.
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Objectives: Standard-of-care for opioid addiction is substitution therapy with 
methadone, buprenorphine, or buprenorphine/naloxone. As EU5 healthcare budgets 
tighten, this study explored how emerging brands may gain a foothold in this increas-
ingly generic market, as payers and prescribers balance clinical need with limited 
funds. MethOds: In February 2015, 253 EU5 psychiatrists were surveyed regarding 
their prescribing for opioid addiction. In addition, 15 payers/payer-advising KOLs who 
